-
-
-
-
-
-
-
Regeneron Reports First Quarter 2026 Financial and Operating Results
-
-
-
-
-
-
-
Regeneron Pharma (REGN) PT Raised to $740 at Cantor Fitzgerald
-
-
-
-
-
-
-
Buy this U.S. large-cap biopharma stock: JPMorgan
-
-
-
-
-
-
-
Regeneron (REGN) Misses Q1 EPS by 26c
-
-
-
-
-
-
-
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
-
-
-
-
-
-
-
Faruqi & Faruqi Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 10, 2025 - REGN
-
-
-
-
-
-
-
Regeneron Pharmaceuticals (REGN) Faces Securities Class Action After Losing $9 Billion Value Following Q3 2024 Earnings Report- Hagens Berman
-
1,214,417 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

